Pharmaceutical company Double Bond Pharmaceutical reports final data from a retrospective study of Temodex showing a statistically significant increase in median survival of 5.6 months for patients with malignant primary brain tumors. The study included 375 patients, of whom 124 received Temodex as an add-on to standard treatment and 251 received standard treatment alone.Median survival was 15.6 months in the Temodex group compared with 10.0 months in the control group. The hazard ratio was 0.61 and the p-value 0.00062."We are very pleased that the final results confirm our preliminary findings, further validating the significant therapeutic benefit of Temodex," says Igor Lokot, CEO of Double Bond Pharmaceutical. "An extension of median survival by 5.6 months is a remarkable result for this patient group. We are now continuing our analyses of the dataset using advanced scientific tools to optimize how SI-053 can be integrated into current care protocols in the most effective way," he continues. In-depth analyses have been submitted for presentation at EANS2026.